FS 120
Alternative Names: FS-120Latest Information Update: 28 Dec 2023
At a glance
- Originator F-star
- Developer F-star Beta; F-star Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD137 antigen agonists; OX40 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Monotherapy) in USA (IV)
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma